Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Lin, Ren ^a   Liu, Qifa ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Diagnosis; Prevention; Treatment; Viral infection

Indexed keywords

ANTIVIRUS AGENT;

ADENOVIRUS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; CYSTITIS; CYTOMEGALOVIRUS; DRUG EFFICACY; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; HEPATITIS VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; INFLUENZA VIRUS; LATENT VIRUS INFECTION; MOLECULAR DIAGNOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; POLYOMA VIRUS; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; REVIEW; RISK FACTOR; TRANSMISSIBLE GASTROENTERITIS VIRUS; VARICELLA ZOSTER VIRUS; VIRAL GASTROENTERITIS; VIRAL RESPIRATORY TRACT INFECTION; VIRUS CULTURE; VIRUS ENCEPHALITIS; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS MENINGITIS; VIRUS REACTIVATION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; TRANSPLANTATION CONDITIONING; VIRUS DISEASES;

EID: 84890266700     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-94     Document Type: Review

References (197)

1. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, Einsele H, Cordonnier C, Bone Marrow Transplant 2005 36 9 757 769 (Pubitemid 41613298)
2. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, et al. Bone Marrow Transplant 2007 40 2 125 136 (Pubitemid 47046210)
3. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Hale G, Waldmann H, Blood 1998 91 8 3079 3083 (Pubitemid 28227562)
4. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation. Xuan L, Jiang X, Sun J, Zhang Y, Huang F, Fan Z, Guo X, Dai M, Liu C, Yu G, et al. Transplantation 2013 96 6 560 566
5. Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. Lv M, Huang XJ, J Hematol Oncol 2012 5 10
6. Diagnostic virology. Storch GA, Clin Infect Dis 2000 31 3 739 751 (Pubitemid 32295496)
7. Detection and monitoring of virus infections by real-time PCR. Watzinger F, Ebner K, Lion T, Mol Aspects Med 2006 27 2-3 254 298
8. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients. Sahin DG, Gunduz E, Kasifoglu N, Akay OM, Us T, Gulbas Z, Adv Ther 2013 30 8 784 791
9. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. Klein A, Miller KB, Sprague K, DesJardin JA, Snydman DR, Bone Marrow Transplant 2011 46 2 294 299
10. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD, N Engl J Med 1991 325 23 1601 1607
11. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Green ML, Leisenring W, Stachel D, Pergam SA, Sandmaier BM, Wald A, Corey L, Boeckh M, Biol Blood Marrow Transplant 2012 18 11 1687 1699
12. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, et al. Blood 2012 119 11 2644 2656
13. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M, Blood Cells Mol Dis 2008 40 1 63 67 (Pubitemid 350192302)
14. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, et al. N Engl J Med 1994 330 17 1185 1191 (Pubitemid 24121987)
15. Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Ali N, Adil SN, Shaikh MU, Moosajee M, Masood N, Exp Hematol Oncol 2012 1 1 13
16. Post-transplant lymphoproliferative disorder: a review. Loren AW, Porter DL, Stadtmauer EA, Tsai DE, Bone Marrow Transplant 2003 31 3 145 155 (Pubitemid 36305567)
17. Prevention and treatment of viral infections in stem cell transplant recipients. Ljungman P, Br J Haematol 2002 118 1 44 57 (Pubitemid 34779516)
18. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE, Moss PA, Milligan DW, Blood 2002 100 5 1619 1627 (Pubitemid 34925137)
19. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Nichols WG, Gooley T, Boeckh M, Biol Blood Marrow Transplant 2001 7 Suppl 11S 15S (Pubitemid 33734763)
20. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Martino R, Porras RP, Rabella N, Williams JV, Ramila E, Margall N, Labeaga R, Crowe JJ, Coll P, Sierra J, Biol Blood Marrow Transplant 2005 11 10 781 796 (Pubitemid 41403760)
21. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Nichols WG, Guthrie KA, Corey L, Boeckh M, Clin Infect Dis 2004 39 9 1300 1306 (Pubitemid 39458515)
22. Increasing incidence of adenovirus disease in bone marrow transplant recipients. Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak GV, McAuliffe T, Camitta B, Horowitz MM, Bunin N, et al. J Infect Dis 1994 169 4 775 781 (Pubitemid 24102109)
23. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolston K, Przepiorka D, Mirza NQ, Yousuf HM, Luna M, et al. Clin Infect Dis 1996 23 5 1033 1037 (Pubitemid 26367489)
24. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Ljungman P, de la Camara R, Cordonnier C, Einsele H, Engelhard D, Reusser P, Styczynski J, Ward K, Bone Marrow Transplant 2008 42 4 227 240
25. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, Ljungman P, Engelhard D, Bone Marrow Transplant 2009 43 10 757 770
26. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P, Clin Infect Dis 2013 56 2 258 266
27. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Peck AJ, Englund JA, Kuypers J, Guthrie KA, Corey L, Morrow R, Hackman RC, Cent A, Boeckh M, Blood 2007 110 5 1681 1688 (Pubitemid 47443987)
28. Human herpesvirus 6: infection and disease following autologous and allogeneic bone marrow transplantation. Kadakia MP, Rybka WB, Stewart JA, Patton JL, Stamey FR, Elsawy M, Pellett PE, Armstrong JA, Blood 1996 87 12 5341 5354 (Pubitemid 26189878)
29. Human herpesvirus type 6 and human herpesvirus type 7 infections of the central nervous system. Dewhurst S, Herpes 2004 11 Suppl 2 105A 111A
30. Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. Yoshikawa T, Asano Y, Ihira M, Suzuki K, Ohashi M, Suga S, Kudo K, Horibe K, Kojima S, Kato K, et al. J Infect Dis 2002 185 7 847 853 (Pubitemid 34274426)
31. Human herpesvirus 6 infection after allogeneic stem cell transplantation: incidence, outcome, and factors associated with HHV-6 reactivation. Jeulin H, Agrinier N, Guery M, Salmon A, Clement L, Bordigoni P, Venard V, Transplantation 2013 95 10 1292 1298
32. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. Ljungman P, Singh N, J Clin Virol 2006 37 Suppl 1 87 S91
33. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, Witherspoon RP, Bensinger W, Flowers ME, Martin P, et al. Blood 2001 97 11 3380 3389
34. Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the infectious diseases working party of the European group for blood and marrow transplantation. Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, et al. Clin Infect Dis 2013 57 6 794 802
35. Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo. McGoldrick SM, Bleakley ME, Guerrero A, Turtle CJ, Yamamoto TN, Pereira SE, Delaney CS, Riddell SR, Blood 2013 121 14 2796 2803
36. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, et al. Blood 2002 99 12 4357 4363 (Pubitemid 34627201)
37. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. Xuan L, Huang F, Fan Z, Zhou H, Zhang X, Yu G, Zhang Y, Liu C, Sun J, Liu Q, J Hematol Oncol 2012 5 46
38. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Huan C, Kai-yan L, Lan-ping X, Dai-hong L, Yu-hong C, Xiang-yu Z, Wei H, Xiao-hui Z, Yu W, Yuan-yuan Z, et al. J Hematol Oncol 2012 5 29
39. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Matthes-Martin S, Feuchtinger T, Shaw PJ, Engelhard D, Hirsch HH, Cordonnier C, Ljungman P, Transpl Infect Dis 2012 14 6 555 563
40. Respiratory viral infections in transplant recipients. Ison MG, Antivir Ther 2007 12 4 Pt B 627 638 (Pubitemid 47235505)
41. Role of cell culture for virus detection in the age of technology. Leland DS, Ginocchio CC, Clin Microbiol Rev 2007 20 1 49 78 (Pubitemid 46167768)
42. The diagnosis of viral respiratory disease in older adults. Talbot HK, Falsey AR, Clin Infect Dis 2010 50 5 747 751
43. Cytomegalovirus load in whole blood is more reliable for predicting and assessing CMV disease than pp 65 antigenaemia. Hardie DR, Korsman SN, Hsiao NY, J Virol Methods 2013 193 1 166 168
44. Significance of human herpesviruses to transplant recipients. Yoshikawa T, Curr Opin Infect Dis 2003 16 6 601 606
45. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, Numata A, et al. Bone Marrow Transplant 2002 29 7 599 606 (Pubitemid 34537721)
46. Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. Li H, Dummer JS, Estes WR, Meng S, Wright PF, Tang YW, J Clin Microbiol 2003 41 1 187 191 (Pubitemid 36098574)
47. Epstein-Barr Virus (EBV) load determination using real-time quantitative polymerase chain reaction. Fan H, Robetorye RS, Methods Mol Biol 2013 999 231 243
48. Lymphomatoid granulomatosis masquerading as interstitial pneumonia in a 66-year-old man: a case report and review of literature. Makol A, Kosuri K, Tamkus D, de Calaca MW, Chang HT, J Hematol Oncol 2009 2 39
49. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, et al. Blood 1998 92 5 1549 1555 (Pubitemid 28406858)
50. Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, et al. Blood 2013 121 26 5113 5123
51. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, et al. Blood 2002 99 11 3916 3922 (Pubitemid 35332029)
52. Herpes virus-related lymphoproliferative disorders following allogeneic bone marrow transplantation: clinical and biological characteristics of six cases. Brion A, Cahn JY, Mougin C, Angonin R, Flesch M, Deschaseaux ML, Plouvier E, Deconinck E, Voillat L, Racadot E, et al. Nouv Rev Fr Hematol 1995 37 6 289 296 (Pubitemid 26033866)
53. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. Erard V, Chien JW, Kim HW, Nichols WG, Flowers ME, Martin PJ, Corey L, Boeckh M, J Infect Dis 2006 193 12 1619 1625 (Pubitemid 43839464)
54. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Ghosh S, Champlin RE, Englund J, Giralt SA, Rolston K, Raad I, Jacobson K, Neumann J, Ippoliti C, Mallik S, et al. Bone Marrow Transplant 2000 25 7 751 755 (Pubitemid 30189516)
55. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Lewinsohn DM, Bowden RA, Mattson D, Crawford SW, Antimicrob Agents Chemother 1996 40 11 2555 2557 (Pubitemid 26367642)
56. Acyclovir prophylaxis of herpes-simplex-virus infections. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS, N Engl J Med 1981 305 2 63 67
57. Vaccination of hematopoietic cell transplant recipients. Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, Small T, Bone Marrow Transplant 2009 44 8 521 526
58. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cheuk DK, Chiang AK, Lee TL, Chan GC, Ha SY, Cochrane Database Syst Rev 2011 3 6505
59. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS and ELN. Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P, Transpl Infect Dis 2013 15 3 219 232
60. Viral pneumonia. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR, Lancet 2011 377 9773 1264 1275
61. Viral pneumonias other than cytomegalovirus in transplant recipients. Barton TD, Blumberg EA, Clin Chest Med 2005 26 4 707 720 (Pubitemid 41563268)
62. Viral infections in immunocompromised patients: what's new with respiratory viruses? Ison MG, Hayden FG, Curr Opin Infect Dis 2002 15 4 355 367 (Pubitemid 34816423)
63. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Symeonidis N, Jakubowski A, Pierre-Louis S, Jaffe D, Pamer E, Sepkowitz K, O'Reilly RJ, Papanicolaou GA, Transpl Infect Dis 2007 9 2 108 113 (Pubitemid 46669079)
64. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, Brinch L, Brune M, De La Camara R, Dekker A, et al. Bone Marrow Transplant 2001 28 5 479 484 (Pubitemid 33069626)
65. Cytomegalovirus pneumonia in hematopoietic stem cell recipients. Travi G, Pergam SA, J Intensive Care Med 2013 PMID 23753231
66. Interstitial pneumonitis after BMT: 15 years experience in a single institution. Granena A, Carreras E, Rozman C, Salgado C, Sierra J, Algara M, Rovira M, Valls A, Bone Marrow Transplant 1993 11 6 453 458 (Pubitemid 23203893)
67. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L, Blood 2003 101 2 407 414 (Pubitemid 36077556)
68. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, et al. Blood 2001 98 4 972 978
69. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Schmidt-Hieber M, Schwender J, Heinz WJ, Zabelina T, Kuhl JS, Mousset S, Schuttrumpf S, Junghanss C, Silling G, Basara N, et al. Haematologica 2011 96 1 142 149
70. Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. Wu M, Huang F, Jiang X, Fan Z, Zhou H, Liu C, Jiang Q, Zhang Y, Zhao K, Xuan L, et al. PLoS One 2013 8 10 77805
71. Central nervous system infections in immunocompromised patients: update on diagnostics and therapy. Schmidt-Hieber M, Zweigner J, Uharek L, Blau IW, Thiel E, Leuk Lymphoma 2009 50 1 24 36
72. Astrovirus infection in children. Walter JE, Mitchell DK, Curr Opin Infect Dis 2003 16 3 247 253 (Pubitemid 36677320)
73. Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. van Kraaij MG, Dekker AW, Verdonck LF, van Loon AM, Vinje J, Koopmans MP, Rozenberg-Arska M, Bone Marrow Transplant 2000 26 3 299 303 (Pubitemid 30614410)
74. Rotavirus infection in adults. Anderson EJ, Weber SG, Lancet Infect Dis 2004 4 2 91 99 (Pubitemid 38169275)
75. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Yusuf U, Hale GA, Carr J, Gu Z, Benaim E, Woodard P, Kasow KA, Horwitz EM, Leung W, Srivastava DK, et al. Transplantation 2006 81 10 1398 1404 (Pubitemid 43847149)
76. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Ljungman P, Ribaud P, Eyrich M, Matthes-Martin S, Einsele H, Bleakley M, Machaczka M, Bierings M, Bosi A, Gratecos N, et al. Bone Marrow Transplant 2003 31 6 481 486 (Pubitemid 36511815)
77. Norovirus infection in pediatric hematopoietic stem cell transplantation recipients: incidence, risk factors, and outcome. Robles JD, Cheuk DK, Ha SY, Chiang AK, Chan GC, Biol Blood Marrow Transplant 2012 18 12 1883 1889
78. Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients. van Burik JA, Lawatsch EJ, DeFor TE, Weisdorf DJ, Biol Blood Marrow Transplant 2001 7 12 674 679 (Pubitemid 34055820)
79. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Locasciulli A, Testa M, Valsecchi MG, Bacigalupo A, Solinas S, Tomas JF, Ljungman P, Alberti A, Transplantation 1999 68 10 1486 1491
80. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Lalazar G, Rund D, Shouval D, Br J Haematol 2007 136 5 699 712
81. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Locasciulli A, Bruno B, Alessandrino EP, Meloni G, Arcese W, Bandini G, Cassibba V, Rotoli B, Morra E, Majolino I, et al. Bone Marrow Transplant 2003 31 4 295 300 (Pubitemid 36336234)
82. Update on epidemiology of hepatitis B and C in China. Cui Y, Jia J, J Gastroenterol Hepatol 2013 28 Suppl 1 7 10
83. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, Kim S, Flowers ME, McDonald GB, Hepatology 1999 29 6 1893 1899 (Pubitemid 29247066)
84. Multivariate analysis of risk factors for hemorrhagic cystitis after hematopoietic stem cell transplantation. Tsuboi K, Kishi K, Ohmachi K, Yasuda Y, Shimizu T, Inoue H, Matsumoto M, Hattori K, Yoshiba F, Watanabe S, et al. Bone Marrow Transplant 2003 32 9 903 907 (Pubitemid 37369268)
85. Hemorrhagic cystitis in a cohort of pediatric transplantations: incidence, treatment, outcome, and risk factors. Kloos RQ, Boelens JJ, de Jong TP, Versluys B, Bierings M, Biol Blood Marrow Transplant 2013 19 8 1263 1266
86. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. Bedi A, Miller CB, Hanson JL, Goodman S, Ambinder RF, Charache P, Arthur RR, Jones RJ, J Clin Oncol 1995 13 5 1103 1109
87. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Leung AY, Mak R, Lie AK, Yuen KY, Cheng VC, Liang R, Kwong YL, Bone Marrow Transplant 2002 29 6 509 513 (Pubitemid 34428720)
88. Cytomegalovirus is a potential risk factor for late-onset hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation. Han TT, Xu LP, Liu DH, Liu KY, Fu HX, Zhao XY, Zhao XS, Huang XJ, Am J Hematol 2013 doi: 10.1002/ajh.23584
89. Adenovirus is a key pathogen in hemorrhagic cystitis associated with bone marrow transplantation. Akiyama H, Kurosu T, Sakashita C, Inoue T, Mori S, Ohashi K, Tanikawa S, Sakamaki H, Onozawa Y, Chen Q, et al. Clin Infect Dis 2001 32 9 1325 1330 (Pubitemid 32405905)
90. Cytomegalovirus and Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation. Tsao SY, Chang KC, Chen YP, Yeh YM, Su WC, Chen TY, Ann Hematol 2011 90 1 113 114
91. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. Manez R, Breinig MC, Linden P, Wilson J, Torre-Cisneros J, Kusne S, Dummer S, Ho M, J Infect Dis 1997 176 6 1462 1467 (Pubitemid 27518144)
92. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretta A, Labirio M, Paulli M, et al. Am J Transplant 2007 7 6 1648 1655 (Pubitemid 46776261)
93. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM, Blood 1988 72 2 520 529
94. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M, Haematologica 2006 91 8 1059 1067 (Pubitemid 44204772)
95. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, et al. Blood 1999 94 7 2208 2216 (Pubitemid 29467666)
96. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Meijer E, Cornelissen JJ, Curr Opin Hematol 2008 15 6 576 585
97. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation. Chiang KY, Hazlett LJ, Godder KT, Abhyankar SH, Christiansen NP, van Rhee F, Lee CG, Bridges K, Parrish RS, Henslee-Downey PJ, Bone Marrow Transplant 2001 28 12 1117 1123 (Pubitemid 34082966)
98. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Nozzoli C, Bartolozzi B, Guidi S, Orsi A, Vannucchi AM, Leoni F, Bosi A, Leuk Lymphoma 2006 47 1 167 169 (Pubitemid 43101743)
99. Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder. Shimizu H, Saitoh T, Koya H, Yuzuriha A, Hoshino T, Hatsumi N, Takada S, Nagaki T, Nojima Y, Sakura T, Int J Hematol 2011 94 5 495 498
100. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Kittan NA, Beier F, Kurz K, Niller HH, Egger L, Jilg W, Andreesen R, Holler E, Hildebrandt GC, Transpl Infect Dis 2011 13 5 524 530
101. Treatment advances in posttransplant lymphoproliferative disease. DiNardo CD, Tsai DE, Curr Opin Hematol 2010 17 4 368 374
102. Definitions of cytomegalovirus infection and disease in transplant recipients. Ljungman P, Griffiths P, Paya C, Clin Infect Dis 2002 34 8 1094 1097 (Pubitemid 34289682)
103. Cytomegalovirus in hematopoietic stem cell transplant recipients. Ljungman P, Hakki M, Boeckh M, Infect Dis Clin North Am 2010 24 2 319 337
104. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. Meyers JD, Flournoy N, Thomas ED, J Infect Dis 1980 142 3 338 346 (Pubitemid 10024569)
105. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation. Kawamura K, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, Sato M, Machishima T, Terasako K, Kimura SI, et al. Transpl Infect Dis 2013 15 5 457 465
106. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Dykewicz CA, Kaplan JE, MMWR Recomm Rep 2000 49 RR-10 1 125 E1-E7
107. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. Liesveld JL, Abboud CN, Ifthikharuddin JJ, Lancet JE, Wedow LA, Oliva J, Stamm CG, Nichols D, Biol Blood Marrow Transplant 2002 8 12 662 665 (Pubitemid 36097805)
108. Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Orlowski RZ, Mills SR, Hartley EE, Ye X, Piantadosi S, Ambinder RF, Gore SD, Miller CB, Leuk Lymphoma 2004 45 11 2215 2219 (Pubitemid 39504315)
109. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. Hoglund M, Ljungman P, Weller S, J Antimicrob Chemother 2001 47 6 855 861 (Pubitemid 32519834)
110. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Blot N, Schneider P, Young P, Janvresse C, Dehesdin D, Tron P, Vannier JP, Bone Marrow Transplant 2000 26 8 903 905
111. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, LeGore J, J Infect Dis 1983 147 4 737 743 (Pubitemid 13088249)
112. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Feldman S, Lott L, Pediatrics 1987 80 4 465 472 (Pubitemid 17139665)
113. Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients. Weinstock DM, Boeckh M, Sepkowitz KA, Biol Blood Marrow Transplant 2006 12 10 1096 1097
114. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Ljungman P, Wilczek H, Gahrton G, Gustavsson A, Lundgren G, Lonnqvist B, Ringden O, Wahren B, Bone Marrow Transplant 1986 1 2 185 192 (Pubitemid 18048960)
115. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Perren TJ, Powles RL, Easton D, Stolle K, Selby PJ, Am J Med 1988 85 2A 99 101
116. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA, Blood 2006 107 5 1800 1805 (Pubitemid 43289356)
117. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Oshima K, Takahashi T, Mori T, Matsuyama T, Usuki K, Asano-Mori Y, Nakahara F, Okamoto S, Kurokawa M, Kanda Y, Transpl Infect Dis 2010 12 5 421 427
118. Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation. Serota FT, Starr SE, Bryan CK, Koch PA, Plotkin SA, August CS, JAMA 1982 247 15 2132 2135 (Pubitemid 12139594)
119. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. Shepp DH, Dandliker PS, Meyers JD, N Engl J Med 1986 314 4 208 212 (Pubitemid 16183151)
120. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL, Cancer Invest 2001 19 1 13 22 (Pubitemid 32233797)
121. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Wassilew SW, Wutzler P, Antiviral Res 2003 59 1 49 56 (Pubitemid 36773890)
122. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Reusser P, Cordonnier C, Einsele H, Engelhard D, Link D, Locasciulli A, Ljungman P, Bone Marrow Transplant 1996 17 5 813 817
123. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H, Iida H, Shimokawa T, Kohno A, Mizuta S, et al. Bone Marrow Transplant 2003 32 8 801 807 (Pubitemid 38455945)
124. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow
125. Rising pp 65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, Davis C, Boeckh M, Blood 2001 97 4 867 874 (Pubitemid 32154267)
126. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Loffler J, et al. Blood 1995 86 7 2815 2820
127. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE, Ann Intern Med 1993 118 3 179 184 (Pubitemid 23034802)
128. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD, Ann Intern Med 1993 118 3 173 178 (Pubitemid 23034801)
129. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Einsele H, Reusser P, Bornhauser M, Kalhs P, Ehninger G, Hebart H, Chalandon Y, Kroger N, Hertenstein B, Rohde F, Blood 2006 107 7 3002 3008
130. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Cooper N, Rao K, Goulden N, Webb D, Amrolia P, Veys P, Bone Marrow Transplant 2008 42 Suppl 2 47 S50
131. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF, Bone Marrow Transplant 2006 37 7 693 698
132. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD, Ann Intern Med 1988 109 10 783 788 (Pubitemid 19046045)
133. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H, Ullmann J, Musso M, Trenschel R, Ribaud P, et al. Blood 2001 97 2 388 392 (Pubitemid 32060322)
134. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S, Byth K, Dubosq MC, Shaw PJ, Micklethwaite KP, et al. Blood 2013 121 18 3745 3758
135. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Liu Q, Xuan L, Liu H, Huang F, Zhou H, Fan Z, Zhao K, Wu M, Xu L, Zhai X, et al. Am J Hematol 2013 88 7 550 555
136. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH, Meijer CJ, van Den Brule AJ, Middeldorp JM, Blood 2001 97 5 1165 1171 (Pubitemid 32183736)
137. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, et al. Blood 2010 115 5 925 935
138. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, et al. Leukemia 2011 25 6 932 938
139. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, et al. Blood 2007 109 6 2571 2578 (Pubitemid 46425904)
140. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Faller DV, Mentzer SJ, Perrine SP, Curr Opin Oncol 2001 13 5 360 367 (Pubitemid 32783414)
141. Treatment of PTLD with rituximab or chemotherapy. Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA, et al. Am J Transplant 2006 6 3 569 576 (Pubitemid 43382145)
142. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, et al. Blood 2006 107 8 3053 3057
143. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, et al. Ann Oncol 2000 11 Suppl 1 113 116
144. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, Rohrlich P, Peuchmaur M, Matthieu-Boue A, Fischer A, et al. Br J Haematol 2001 115 1 112 118 (Pubitemid 32995103)
145. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Styczynski J, Einsele H, Gil L, Ljungman P, Transpl Infect Dis 2009 11 5 383 392
146. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE, Blood 2004 103 10 3979 3981 (Pubitemid 38596322)
147. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, et al. J Clin Oncol 2005 23 27 6481 6488 (Pubitemid 46190239)
148. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, et al. Lancet Oncol 2012 13 2 196 206
149. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Gong JZ, Bayerl MG, Sandhaus LM, Sebastian S, Rehder CW, Routbort M, Lagoo AS, Szabolcs P, Chiu J, Comito M, et al. Am J Surg Pathol 2006 30 3 328 336 (Pubitemid 43740164)
150. Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab. Maximiano AC, Sanchez RA, Cantos SDIB, Mendez GM, Ronco IS, Provencio PM, Clin Transl Oncol 2010 12 10 701 703
151. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Bonney DK, Htwe EE, Turner A, Kelsey A, Shabani A, Hughes S, Hughes I, Wynn RF, Pediatr Blood Cancer 2012 58 3 459 461
152. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Czyzewski K, Styczynski J, Krenska A, Debski R, Zajac-Spychala O, Wachowiak J, Wysocki M, Leuk Lymphoma 2013 54 3 503 506
153. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, et al. J Clin Oncol 2007 25 11 1350 1356 (Pubitemid 46706881)
154. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K, Scand J Infect Dis 2007 39 3 235 244 (Pubitemid 46322808)
155. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Tokimasa S, Hara J, Osugi Y, Ohta H, Matsuda Y, Fujisaki H, Sawada A, Kim JY, Sashihara J, Amou K, et al. Bone Marrow Transplant 2002 29 7 595 598 (Pubitemid 34537720)
156. Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients. Rapaport D, Engelhard D, Tagger G, Or R, Frenkel N, Transpl Infect Dis 2002 4 1 10 16 (Pubitemid 34786820)
157. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Zerr DM, Gupta D, Huang ML, Carter R, Corey L, Clin Infect Dis 2002 34 3 309 317 (Pubitemid 34062230)
158. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Gantt S, Casper C, Curr Opin Infect Dis 2011 24 4 295 301
159. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. Luppi M, Barozzi P, Schulz TF, Setti G, Staskus K, Trovato R, Narni F, Donelli A, Maiorana A, Marasca R, et al. N Engl J Med 2000 343 19 1378 1385
160. Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Luppi M, Barozzi P, Schulz TF, Trovato R, Donelli A, Narni F, Sheldon J, Marasca R, Torelli G, Blood 2000 96 7 2355 2357
161. Kaposi's sarcoma after allogeneic bone marrow transplantation. Erer B, Angelucci E, Muretto P, Ripalti M, Rapa S, Gaziev D, Baronciani D, Bone Marrow Transplant 1997 19 6 629 631 (Pubitemid 27139790)
162. Bone marrow failure associated with herpesvirus 8 infection in a patient undergoing autologous peripheral blood stem cell transplantation. Cuzzola M, Irrera G, Iacopino O, Cuzzocrea A, Messina G, Console G, Iacopino P, Morabito F, Clin Infect Dis 2003 37 7 102 e106
163. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, Ushay HM, Sepkowitz KA, Bone Marrow Transplant 2002 29 4 321 327 (Pubitemid 34229037)
164. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Shah JN, Chemaly RF, Blood 2011 117 10 2755 2763
165. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M, Blood 2001 98 3 573 578
166. Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Elizaga J, Olavarria E, Apperley J, Goldman J, Ward K, Clin Infect Dis 2001 32 3 413 418 (Pubitemid 32173627)
167. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Milano F, Campbell AP, Guthrie KA, Kuypers J, Englund JA, Corey L, Boeckh M, Blood 2010 115 10 2088 2094
168. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ, Biol Blood Marrow Transplant 2009 15 10 1143 1238
169. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, Champlin RE, Aguilera EA, Tarrand JJ, Raad II, Medicine (Baltimore) 2006 85 5 278 287 (Pubitemid 44401460)
170. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H, Kuypers J, Kim H, Gnann J, Whitley R, Clin Infect Dis 2007 44 2 245 249 (Pubitemid 46079989)
171. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation-a compassionate use experience. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FJ, Bone Marrow Transplant 2000 25 2 161 165 (Pubitemid 30087985)
172. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. de Fontbrune FS, Robin M, Porcher R, Scieux C, de Latour RP, Ferry C, Rocha V, Boudjedir K, Devergie A, Bergeron A, et al. Clin Infect Dis 2007 45 8 1019 1024 (Pubitemid 47580353)
173. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L, J Infect Dis 2001 184 3 350 354 (Pubitemid 32662183)
174. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Vu D, Peck AJ, Nichols WG, Varley C, Englund JA, Corey L, Boeckh M, Clin Infect Dis 2007 45 2 187 193 (Pubitemid 47041009)
175. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Yousuf H, Regnery H, Klimov AI, Cox NJ, et al. Clin Infect Dis 1998 26 6 1418 1424 (Pubitemid 28270175)
176. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ, J Infect Dis 1995 172 5 1352 1355
177. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Johny AA, Clark A, Price N, Carrington D, Oakhill A, Marks DI, Bone Marrow Transplant 2002 29 2 113 115 (Pubitemid 34144842)
178. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. Fraaij PL, van der Vries E, Beersma MF, Riezebos-Brilman A, Niesters HG, van der Eijk AA, de Jong MD, Reis MD, Horrevorts AM, Ridwan BU, et al. J Infect Dis 2011 204 5 777 782
179. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto CJ, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, et al. Haematologica 2011 96 8 1231 1235
180. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. Williams JV, Martino R, Rabella N, Otegui M, Parody R, Heck JM, Crowe JJ, J Infect Dis 2005 192 6 1061 1065 (Pubitemid 41266804)
181. Adenovirus infections in adult recipients of blood and marrow transplants. La Rosa AM, Champlin RE, Mirza N, Gajewski J, Giralt S, Rolston KV, Raad I, Jacobson K, Kontoyiannis D, Elting L, et al. Clin Infect Dis 2001 32 6 871 876 (Pubitemid 32524820)
182. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A, Clin Infect Dis 2001 32 9 1290 1297 (Pubitemid 32405900)
183. Severe adenoviral nephritis following bone marrow transplantation: successful treatment with intravenous ribavirin. Liles WC, Cushing H, Holt S, Bryan C, Hackman RC, Bone Marrow Transplant 1993 12 4 409 412 (Pubitemid 23295526)
184. Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy. Chakrabarti S, Collingham KE, Fegan CD, Milligan DW, Bone Marrow Transplant 1999 23 11 1209 1211 (Pubitemid 29259681)
185. Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention. Sivaprakasam P, Carr TF, Coussons M, Khalid T, Bailey AS, Guiver M, Mutton KJ, Turner AJ, Grainger JD, Wynn RF, J Pediatr Hematol Oncol 2007 29 2 81 85 (Pubitemid 46213853)
186. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K, Handgretinger R, Peters C, Schuster FR, Beck R, et al. Br J Haematol 2006 134 1 64 76 (Pubitemid 43830030)
187. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Regn S, Raffegerst S, Chen X, Schendel D, Kolb HJ, Roskrow M, Bone Marrow Transplant 2001 27 1 53 64 (Pubitemid 32124407)
188. Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Roddie C, Paul JP, Benjamin R, Gallimore CI, Xerry J, Gray JJ, Peggs KS, Morris EC, Thomson KJ, Ward KN, Clin Infect Dis 2009 49 7 1061 1068
189. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Endo T, Sakai T, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, Nishio M, Koizumi K, Koike T, Sawada K, Bone Marrow Transplant 2001 27 4 433 436 (Pubitemid 32201352)
190. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. Lau GK, Liang R, Wu PC, Lee CK, Lim WL, Au WY, J Hepatol 1998 28 3 359 368 (Pubitemid 28133537)
191. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Ljungman P, Andersson J, Aschan J, Bjorkstrand B, Hagglund H, Lonnqvist B, Ringden O, Winiarski J, Clin Infect Dis 1996 23 1 167 169 (Pubitemid 26323813)
192. Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia. Giardini C, Galimberti M, Lucarelli G, Polchi P, Angelucci E, Baronciani D, Erer B, Gaziev D, Piga A, Di Gregorio F, et al. Bone Marrow Transplant 1997 20 9 767 772 (Pubitemid 27489183)
193. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Ljungman P, Johansson N, Aschan J, Glaumann H, Lonnqvist B, Ringden O, Sparrelid E, Sonnerborg A, Winiarski J, Gahrton G, Blood 1995 86 4 1614 1618
194. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Balduzzi A, Lucchini G, Hirsch HH, Basso S, Cioni M, Rovelli A, Zincone A, Grimaldi M, Corti P, Bonanomi S, et al. Bone Marrow Transplant 2011 46 7 987 992
195. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, Liang R, Lie AK, Kwong YL, Clin Infect Dis 2005 40 4 528 537 (Pubitemid 40270222)
196. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. Bridges B, Donegan S, Badros A, Am J Hematol 2006 81 7 535 537
197. Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Savona MR, Newton D, Frame D, Levine JE, Mineishi S, Kaul DR, Bone Marrow Transplant 2007 39 12 783 787 (Pubitemid 46901977)